BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2016;14:1821-1830.e6. [DOI: 10.1016/j.cgh.2016.07.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Rolt A, Le D, Hu Z, Wang AQ, Shah P, Singleton M, Hughes E, Dulcey AE, He S, Imamura M, Uchida T, Chayama K, Xu X, Marugan JJ, Liang TJ. Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Infect Dis 2018;217:1761-9. [PMID: 29373739 DOI: 10.1093/infdis/jiy039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
3 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rostaing L, Alric L, Kamar N. Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. Transpl Int 2016;29:1257-65. [DOI: 10.1111/tri.12870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Daniel KE, Said A. Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate. Curr Gastroenterol Rep. 2018;20:20. [PMID: 29623506 DOI: 10.1007/s11894-018-0626-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 You MW, Kim KW, Shim JJ, Pyo J. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis. J Gastroenterol Hepatol 2021;36:601-8. [PMID: 32875681 DOI: 10.1111/jgh.15243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 Ti L, Ng M, Awendila L, Carrieri PM. Hepatitis C virus infection and hospital-related outcomes: a systematic review protocol. BMJ Open 2018;8:e021118. [PMID: 29903795 DOI: 10.1136/bmjopen-2017-021118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Juanbeltz R, Goñi Esarte S, Úriz-Otano JI, Martínez Echeverría A, Elizalde I, Zozaya JM, Castilla J, San Miguel R. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med 2017;129:476-83. [PMID: 28343408 DOI: 10.1080/00325481.2017.1311197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
9 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
10 Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Transplantation 2020;104:2087-96. [PMID: 31978002 DOI: 10.1097/TP.0000000000003115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yamashita Y, Joshita S, Sugiura A, Yamazaki T, Kobayashi H, Wakabayashi SI, Yamada Y, Shibata S, Kunimoto H, Iwadare T, Matsumura M, Miyabayashi C, Okumura T, Ozawa S, Nozawa Y, Kobayashi N, Komatsu M, Fujimori N, Saito H, Umemura T. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res 2021. [PMID: 34216422 DOI: 10.1111/hepr.13689] [Reference Citation Analysis]
12 Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153:996-1005.e1. [PMID: 28642197 DOI: 10.1053/j.gastro.2017.06.012] [Cited by in Crossref: 354] [Cited by in F6Publishing: 346] [Article Influence: 70.8] [Reference Citation Analysis]
13 Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort. Hepat Med 2017;9:67-73. [PMID: 29296102 DOI: 10.2147/HMER.S149578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cursino CN, Monteiro PGO, Duarte GDS, Vieira TBQ, Crisante VC, Giordani F, Xavier AR, de Almeida RMVR, Calil-Elias S. Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C. Pharmacoepidemiol Drug Saf 2019;28:1601-8. [PMID: 31692182 DOI: 10.1002/pds.4904] [Reference Citation Analysis]
15 Lourenço MS, Zitelli PMY, Cunha-Silva M, Oliveira AIN, Oliveira CP, Sevá-Pereira T, Carrilho FJ, Pessoa MG, Mazo DF. Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil. World J Hepatol 2022; 14(1): 195-208 [DOI: 10.4254/wjh.v14.i1.195] [Reference Citation Analysis]
16 Charatcharoenwitthaya P, Wongpaitoon V, Komolmit P, Sukeepaisarnjaroen W, Tangkijvanich P, Piratvisuth T, Sanpajit T, Sutthivana C, Bunchorntavakul C, Sobhonslidsuk A, Chonprasertsuk S, Siripipattanamongkol C, Sethasine S, Tanwandee T; THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC Gastroenterol 2020;20:47. [PMID: 32138687 DOI: 10.1186/s12876-020-01196-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ucciferri C, Occhionero A, Vecchiet J, Falasca K. Cardiac Toxicity Associated with HCV Direct Antiviral Agents. Mediterr J Hematol Infect Dis 2018;10:e2018069. [PMID: 30416701 DOI: 10.4084/MJHID.2018.069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Maan R, van der Meer AJ. Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven? Hepatobiliary Surg Nutr 2020;9:257-9. [PMID: 32355697 DOI: 10.21037/hbsn.2019.10.04] [Reference Citation Analysis]
19 Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. [DOI: 10.1007/s00535-021-01845-5] [Reference Citation Analysis]
20 El Raziky M, Hamdy S, Hamada Y, Abdelaziz NM, Hassany M, Doss W, Zakaria Z. Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00174-3] [Reference Citation Analysis]
21 Miotto N, Mendes LC, Zanaga LP, Lazarini MSK, Goncales ESL, Pedro MN, Goncales FL Jr, Stucchi RSB, Vigani AG. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13:e0199941. [PMID: 29990371 DOI: 10.1371/journal.pone.0199941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
22 Sessa M, Bernardi FF, Vitale A, Schiavone B, Gritti G, Mascolo A, Bertini M, Scavone C, Sportiello L, Rossi F, Capuano A. Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system. J Clin Pharm Ther 2018;43:867-76. [PMID: 30014479 DOI: 10.1111/jcpt.12744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zhang J, Li J, Ma J, Wang H, Yi Y. Human fibroblast growth factor-21 serves as a predictor and prognostic factor in patients with hepatitis B cirrhosis combined with adrenal insufficiency. Exp Ther Med 2018;15:3189-96. [PMID: 29545834 DOI: 10.3892/etm.2018.5840] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, de Knegt RJ, Hansen BE, Janssen HLA, de Man RA, Feld JJ, van der Meer AJ. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 2021;74:1053-63. [PMID: 33242501 DOI: 10.1016/j.jhep.2020.11.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
25 Smith DE, Chen S, Fargnoli A, Lewis T, Galloway AC, Kon ZN, Moazami N. Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors. Semin Thorac Cardiovasc Surg 2021;33:407-15. [PMID: 32621962 DOI: 10.1053/j.semtcvs.2020.06.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Berkan-Kawińska A, Piekarska A, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Berak H, Horban A, Zarębska-Michaluk D, Pabjan P, Buczyńska I, Pazgan-Simon M, Dybowska D, Halota W, Pawłowska M, Klapaczyński J, Mazur W, Czauż-Andrzejuk A, Socha Ł, Laurans Ł, Garlicki A, Sitko M, Jaroszewicz J, Citko J, Dobracka B, Krygier R, Białkowska-Warzecha J, Tronina O, Belica-Wdowik T, Baka-Ćwierz B, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver Int 2021;41:1789-801. [PMID: 33655628 DOI: 10.1111/liv.14858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
29 Chen K, Lu P, Song R, Zhang J, Tao R, Wang Z, Zhang W, Gu M. Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. Medicine (Baltimore) 2017;96:e7568. [PMID: 28746204 DOI: 10.1097/MD.0000000000007568] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
30 Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. J Clin Biochem Nutr 2020;66:245-52. [PMID: 32523252 DOI: 10.3164/jcbn.19-98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Karbeyaz F, Kissling S, Jaklin PJ, Bachofner J, Brunner B, Müllhaupt B, Winder T, Mertens JC, Misselwitz B, von Felten S, Siebenhüner AR. Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center. J Hepatocell Carcinoma 2021;8:565-74. [PMID: 34150679 DOI: 10.2147/JHC.S289955] [Reference Citation Analysis]
32 Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A, Requena S, Cuervas-Mons V, de Mendoza C. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS 2018;32:2347-52. [PMID: 30096074 DOI: 10.1097/QAD.0000000000001966] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
33 Takeda H, Takai A, Iguchi E, Mishima M, Arasawa S, Kumagai K, Eso Y, Shimizu T, Takahashi K, Ueda Y, Taura K, Hatano E, Iijima H, Aoyagi H, Aizaki H, Marusawa H, Wakita T, Seno H. Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus. Carcinogenesis 2021;42:672-84. [PMID: 33617626 DOI: 10.1093/carcin/bgab014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fabrizio C, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G. The elderly and direct antiviral agents: Constraint or challenge? Dig Liver Dis. 2017;49:1036-1042. [PMID: 28651903 DOI: 10.1016/j.dld.2017.05.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Sugimoto R, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, Tanaka H, Eguchi A, Yamamoto N, Kobayashi Y, Hasegawa H, Takei Y. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res 2018;48:337-44. [PMID: 29115717 DOI: 10.1111/hepr.12999] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
36 Cenderello G, Fanizza C, Marenco S, Nicolini LA, Artioli S, Baldissarro I, Dentone C, De Leo P, Di Biagio A. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. Clinicoecon Outcomes Res 2017;9:281-93. [PMID: 28579812 DOI: 10.2147/CEOR.S129859] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Attia D, El Saeed K, Elakel W, El Baz T, Omar A, Yosry A, Elsayed MH, Said M, El Raziky M, Anees M. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther. 2018;47:1296-1305. [PMID: 29504152 DOI: 10.1111/apt.14538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
38 Ma L, Liu J, Wang W, Yang F, Li P, Cai S, Zhou X, Chen X, Zhuang X, Zhang H, Cao G. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020;16:675-686. [PMID: 32223423 DOI: 10.2217/fon-2019-0845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Papanikolaou IS, Papadimitropoulos V. Editorial: are the "miraculous" direct-acting antiviral (DAA) regimens really safe? Aliment Pharmacol Ther 2018;47:1318-9. [PMID: 29644736 DOI: 10.1111/apt.14580] [Reference Citation Analysis]
40 Mínguez C, García-Deltoro M, Flores J, Galindo MJ, Montero M, Reus S, Carmena J, Masiá M, Amador C, Ortega E; on the behalf of the COINFECOVA-2 study group. Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. AIDS 2018;32:337-46. [PMID: 29309345 DOI: 10.1097/QAD.0000000000001699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Sarmento-Castro R, Méndez J, Horta A, Gonçalves C, Vasconcelos O, Seabra J, Abreu M, Gonçalves MJ, Santos MJ, Tavares AP. Hepatitis C treatment outcome in former or current intravenous drug users coinfected with HIV, with or without directly observed therapy. Infect Dis (Lond) 2021;53:9-18. [PMID: 32820689 DOI: 10.1080/23744235.2020.1806352] [Reference Citation Analysis]
42 Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc 2017;20. [PMID: 29116684 DOI: 10.1002/jia2.25013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]